Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Disparities in SARS-CoV-2 seroprevalence among individuals presenting for care in central North Carolina over a six-month period

View ORCID ProfileCesar A. Lopez, Clark H. Cunningham, Sierra Pugh, Katerina Brandt, Usaphea P. Vanna, Matthew J. Delacruz, Quique Guerra, Samuel Jacob Goldstein, Yixuan J. Hou, Margaret Gearhart, Christine Wiethorn, Candace Pope, Carolyn Amditis, Kathryn Pruitt, Cinthia Newberry-Dillon, John Schmitz, Lakshmanane Premkumar, Adaora A. Adimora, Michael Emch, Ross Boyce, Allison E. Aiello, Bailey K. Fosdick, Daniel B. Larremore, Aravinda M. de Silva, Jonathan J Juliano, Alena J. Markmann
doi: https://doi.org/10.1101/2021.03.25.21254320
Cesar A. Lopez
1Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cesar A. Lopez
Clark H. Cunningham
2Department of Genetics, University of North Carolina School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sierra Pugh
3Department of Statistics, Colorado State University, Fort Collins, CO, 80523, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katerina Brandt
4Department of Geography, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA; Carolina Population Center, Chapel Hill, NC 27516, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Usaphea P. Vanna
1Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew J. Delacruz
1Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Quique Guerra
1Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel Jacob Goldstein
5Department of Environmental Sciences and Engineering, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yixuan J. Hou
6Department of Epidemiology, University of North Carolina at Chapel Hill School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margaret Gearhart
7McLendon Clinical Laboratories, UNC Healthcare, Chapel Hill, NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Wiethorn
8Johnston Health Laboratories, Johnston Health, Smithfield, NC 27577
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Candace Pope
8Johnston Health Laboratories, Johnston Health, Smithfield, NC 27577
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolyn Amditis
9Rex Healthcare Laboratory, UNC Healthcare, Chapel Hill, NC 27607, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathryn Pruitt
10Chatham Clinical Laboratory, Chatham Hospital, Siler City, NC 27344, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cinthia Newberry-Dillon
10Chatham Clinical Laboratory, Chatham Hospital, Siler City, NC 27344, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Schmitz
11Department of Pathology & Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lakshmanane Premkumar
1Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adaora A. Adimora
6Department of Epidemiology, University of North Carolina at Chapel Hill School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
12Department of Medicine, Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Emch
4Department of Geography, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA; Carolina Population Center, Chapel Hill, NC 27516, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ross Boyce
12Department of Medicine, Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allison E. Aiello
6Department of Epidemiology, University of North Carolina at Chapel Hill School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bailey K. Fosdick
3Department of Statistics, Colorado State University, Fort Collins, CO, 80523, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel B. Larremore
13Department of Computer Science & BioFrontiers Institute, University of Colorado Boulder, Boulder, CO, 80303, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aravinda M. de Silva
1Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan J Juliano
6Department of Epidemiology, University of North Carolina at Chapel Hill School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
12Department of Medicine, Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alena J. Markmann
12Department of Medicine, Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: alena.markmann@unchealth.unc.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Robust community-level SARS-CoV-2 prevalence estimates have been difficult to obtain in the American South and outside of major metropolitan areas. Furthermore, though some previous studies have investigated the association of demographic factors such as race with SARS-CoV-2 exposure risk, fewer have correlated exposure risk to surrogates for socioeconomic status such as health insurance coverage.

Methods We used a highly specific serological assay utilizing the receptor binding domain of the SARS-CoV-2 spike-protein to identify SARS-CoV-2 antibodies in remnant blood samples collected by the University of North Carolina Health system. We estimated the prevalence of SARS-CoV-2 in this cohort with Bayesian regression, as well as the association of critical demographic factors with higher prevalence odds.

Findings Between April 21st and October 3rd of 2020, a total of 9,624 unique samples were collected from clinical sites in central NC and we observed a seroprevalence increase from 2·9 (1·7, 4·3) to 9·1 (7·2, 11·1) over the study period. Individuals who identified as Latinx were associated with the highest odds ratio of SARS-CoV-2 exposure at 7·77 overall (5·20, 12·10). Increased odds were also observed among Black individuals and individuals without public or private health insurance.

Interpretation Our data suggests that for this care-accessing cohort, SARS-CoV-2 seroprevalence was significantly higher than cumulative total cases reported for the study geographical area six months into the COVID-19 pandemic in North Carolina. The increased odds of seropositivity by ethnoracial grouping as well as health insurance highlights the urgent and ongoing need to address underlying health and social disparities in these populations.

Evidence before this study We searched PubMed for studies published through March 21st, 2021. We used search terms that included “COVID-19”, “SARS-CoV-2”, “prevalence” and “seroprevalence”. Our search resulted in 399 papers, from which we identified 58 relevant studies describing SARS-CoV-2 seroprevalence at sites around the United States from March 1 to December 9, 2020, 12 of which utilized remnant clinical samples and three of which overlapped with our study area. Most notably, one study of 4,422 asymptomatic inpatients and outpatients in central NC from April 28-June 19, 2020 found an estimated seroprevalence of 0·7 −0·8%, and another study of 177,919 inpatients and outpatients (3,817 from NC) from July 27-September 24, 2020 found an estimated seroprevalence of 2·5 −6·8%.

Added value of this study This is the largest SARS-CoV-2 seroprevalence cohort published to date in NC. Importantly, we used a Bayesian framework to account for uncertainty in antibody assay sensitivity and specificity and investigated seropositivity by important demographic variables that have not yet been studied in this context in NC. This study corroborates other reports that specific demographic factors including race, ethnicity and the lack of public or private insurance are associated with elevated risk of SARS-CoV-2 infection. Furthermore, in a subset of serum samples, we identify other SARS-CoV-2 antibodies elicited by these individuals, including functionally neutralizing antibodies.

Implications of all the available evidence It is difficult to say the exact seroprevalence in the central North Carolina area, but a greater proportion of the population accessing healthcare has been infected by SARS-CoV-2 than is reflected by infection cases confirmed by molecular testing. Furthermore, local governments need to prioritize addressing the many forms of systemic racism and socioeconomic disadvantage that drive SARS-CoV-2 exposure risk, such as residential and occupational risk, and an urgent need to provide access to SARS-CoV-2 testing and vaccination to these groups.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by funds from the NC Department of Health and Human Services, Division of Public Health (Contract 00041877) and the SeroNet program of the National Cancer Institute (1U01CA261277-01). Funding sources played no role in study design, in the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All data for this study were collected under UNC IRB #20-0791, which is conducted under Good Clinical Research Practices (GCP) and compliant with institutional IRB oversight. De-identified samples used for assay validation were collected under UNC IRBs #20-0913 and #08-0895.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* co-first authors

Data Availability

Data Sharing Deidentified individual data will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 30, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Disparities in SARS-CoV-2 seroprevalence among individuals presenting for care in central North Carolina over a six-month period
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Disparities in SARS-CoV-2 seroprevalence among individuals presenting for care in central North Carolina over a six-month period
Cesar A. Lopez, Clark H. Cunningham, Sierra Pugh, Katerina Brandt, Usaphea P. Vanna, Matthew J. Delacruz, Quique Guerra, Samuel Jacob Goldstein, Yixuan J. Hou, Margaret Gearhart, Christine Wiethorn, Candace Pope, Carolyn Amditis, Kathryn Pruitt, Cinthia Newberry-Dillon, John Schmitz, Lakshmanane Premkumar, Adaora A. Adimora, Michael Emch, Ross Boyce, Allison E. Aiello, Bailey K. Fosdick, Daniel B. Larremore, Aravinda M. de Silva, Jonathan J Juliano, Alena J. Markmann
medRxiv 2021.03.25.21254320; doi: https://doi.org/10.1101/2021.03.25.21254320
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Disparities in SARS-CoV-2 seroprevalence among individuals presenting for care in central North Carolina over a six-month period
Cesar A. Lopez, Clark H. Cunningham, Sierra Pugh, Katerina Brandt, Usaphea P. Vanna, Matthew J. Delacruz, Quique Guerra, Samuel Jacob Goldstein, Yixuan J. Hou, Margaret Gearhart, Christine Wiethorn, Candace Pope, Carolyn Amditis, Kathryn Pruitt, Cinthia Newberry-Dillon, John Schmitz, Lakshmanane Premkumar, Adaora A. Adimora, Michael Emch, Ross Boyce, Allison E. Aiello, Bailey K. Fosdick, Daniel B. Larremore, Aravinda M. de Silva, Jonathan J Juliano, Alena J. Markmann
medRxiv 2021.03.25.21254320; doi: https://doi.org/10.1101/2021.03.25.21254320

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (134)
  • Cardiovascular Medicine (1746)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (651)
  • Epidemiology (10770)
  • Forensic Medicine (8)
  • Gastroenterology (582)
  • Genetic and Genomic Medicine (2930)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1917)
  • Health Policy (832)
  • Health Systems and Quality Improvement (740)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12494)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (319)
  • Neurology (2778)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (553)
  • Occupational and Environmental Health (596)
  • Oncology (1451)
  • Ophthalmology (440)
  • Orthopedics (172)
  • Otolaryngology (254)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (378)
  • Pediatrics (863)
  • Pharmacology and Therapeutics (361)
  • Primary Care Research (333)
  • Psychiatry and Clinical Psychology (2626)
  • Public and Global Health (5335)
  • Radiology and Imaging (1001)
  • Rehabilitation Medicine and Physical Therapy (592)
  • Respiratory Medicine (721)
  • Rheumatology (329)
  • Sexual and Reproductive Health (288)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (124)